PROCEPT BioRobotics (PRCT)
Robotic platform for autonomous, heat-free waterjet ablation of prostate tissue.
Something off on this page? Send us feedback.
Commercializes robotic surgical systems for Aquablation — an autonomous, image-guided waterjet removal of prostate tissue — sold as capital equipment with recurring single-use disposable handpieces. The platform serves benign prostatic hyperplasia today and is in a pivotal randomized trial for localized prostate cancer.
Designs and commercializes robotic systems that deliver Aquablation — an autonomous, heat-free waterjet ablation of prostate tissue guided by real-time ultrasound, with removal geometry set by imaging rather than by surgeon technique.
The platform spans AquaBeam, the first-generation device, and HYDROS, cleared by the FDA in August 2024 with AI-augmented planning. Revenue comes from system placements and recurring single-use disposable handpieces, one consumed per procedure.
Commercial activity is concentrated in the U.S. A pivotal randomized trial comparing Aquablation to radical prostatectomy in localized prostate cancer completed enrollment in May 2026; a second arm compares Aquablation to active surveillance.
Procedure volumes depend on saline supply; a 2024 IV-fluid shortage disrupted a share of procedures. Aquablation received Category I CPT recognition effective January 2026.
Company facts
Categories
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 5, 2026 | Truist Financial | Target | $25 | $21 | ||
| Aug 5, 2026 | Evercore ISI | Target | $30 | $23 | ||
| Aug 5, 2026 | Robert W. Baird | Target | $20 | |||
| Aug 5, 2026 | Piper Sandler | Reiterate | Overweight | $35 | $25 | |
| Aug 5, 2026 | Wells Fargo | Target | $34 | $19 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $227.9M · Total debt $77.5M · Total assets $479.4M · Shareholders' equity $340.1M
- Revenue
- $94.5M
- Operating income
- −$27.4M
- Net income
- −$26.9M
No dividends on record.
| Institutions268 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | ≈ 95.81% | 54.87M shares | |
| Insiders15 holders · as of Aug 14, 2026 | 4.63% | 2.65M shares | |
| Strategic holders2 holders · as of Jan 26, 2024 | 24.93% | 14.28M shares | |
| Adds to | 125.37% |
57.27M company shares as of Sep 3, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 125.37%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
CPMG IncStrategic10 percent owner | 19.06% | 10.92M | Form 4filed Mar 21, 2022 ↗ |
BlackRock, Inc.Institution | 8.50% | 4.87M | 13Fas of Jun 30, 2026 |
BlackRock, Inc.Strategic | 5.86% | 3.36M | 13D/Gfiled Jan 26, 2024 ↗ |
T. Rowe Price Investment Management, Inc.Institution | 5.70% | 3.27M | 13Fas of Jun 30, 2026 |
BNP Paribas Asset Management Holding S.A.Institution | 4.93% | 2.82M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 7, 2026 | Larry L. Wood | director, officer: President, CEO | +23,900 | $20.85 |
| Jun 8, 2026 | Barry L. Templin | officer: EVP, Chief Technology Officer | −358 | $28.48 |
| Jun 8, 2026 | Kevin Waters | officer: EVP, CFO | −357 | $28.48 |
| Jun 8, 2026 | Alaleh Nouri | officer: EVP, CLO, CORP. SEC. | −285 | $28.48 |
| Mar 17, 2026 | Kevin Waters | officer: EVP, CFO | −706 | $28.15 |
- Boston Scientific
Dual BPH platforms — Rezum water vapor and GreenLight laser — span office and OR
- Teleflex
Mechanical BPH lift (UroLift) — MIST volume rival delivered in office setting
- Intuitive Surgical
Da Vinci dominates radical prostatectomy — direct WATER IV RP comparator
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| PROCEPT BioRobotics | $22.13 | +0.68% | $1.25B | — | — | 3.7 | +19.3% |
| Boston Scientific | $48.42 | +0.09% | $71.90B | 19.7 | 14.6 | 3.4 | +7.5% |
| Teleflex | $140.89 | +0.03% | $6.24B | — | 15.3 | 2.4 | −27.0% |
| Intuitive Surgical | $372.32 | +0.12% | $131.38B | 42.3 | 32.9 | 11.9 | +18.5% |
| Median | 31.0 | 15.3 | 3.4 | +7.5% |